Valeant Pharmaceuticals International, Inc. VRX
At closeJun 28, 2019, 6:07 PM EDT
Day range unavailable
- YTD
- -100.00%
- 1 year
- -100.00%
- Market cap
- 8.17B
- Revenue (ttm)
- 8.61B
- Profit margin
- -10.65%
- EPS (ttm)
- 6.83
- Shares out
- 349.30M
- P/E ratio
- 3.43
- Forward P/E
- 6.67
- YTD return
- -100.00%
- 1-year return
- -100.00%
- Avg volume
- 6.43M
- Previous close
- 24.11
- 52-week range
- 10.94 – 27.79
- Beta
- -0.93
- Analysts
- Hold
- Price target
- 23.25 (-3.6%)
Key statistics
- Enterprise value
- 32.38B
- PEG ratio
- 3.05
- Price / sales
- 0.95
- Price / book
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -5.40%
- Free cash flow
- 2.52B
- Total cash
- 909.00M
- Total debt
- 25.27B
- Return on equity
- -21.51%
- Short % of float
- 4.72%
- 50-day average
- 23.03
- 200-day average
- 19.85
Analyst view
Consensus: hold
- Target (low)
- 9.00
- Target (mean)
- 23.25
- Target (high)
- 35.00
- Strong buy2
- Buy2
- Hold12
- Sell4
- Strong sell1
Next earnings
Consensus EPS estimate 0.78.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2018 | TD Securities | down | Buy | Hold |
| Jun 5, 2018 | Barclays | up | Equal-Weight | Overweight |
| May 14, 2018 | Mizuho | up | Neutral | Buy |
| Apr 5, 2018 | Mizuho | up | Underperform | Neutral |
| Jan 23, 2018 | Goldman Sachs | init | — | Sell |
| Dec 13, 2017 | JP Morgan | down | Neutral | Underweight |
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- valeant.com
News
TD Ameritrade Traders Adopt Some Old And New Approaches To The Trade War Market In June's IMX 
56 Biggest Movers From Yesterday 
48 Stocks Moving In Tuesday's Mid-Day Session 
40 Stocks Moving In Tuesday's Pre-Market Session 
Valeant, Financials And More: Fast Money Picks For June 29 - Benzinga's Option Alert Recap From April 26
- Watch These 8 Huge Call Purchases In Monday Trade
Benzinga's Option Alert Recap From February 24 
Mr. Wonderful's Election Week Trades For A Trump Victory - Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Your note
Sign in to keep a note on VRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE SCHUTTER RICHARD U | Director | Stock Award(Grant) | May 2, 2018 | 118,787 |
| HALE DAVID ROBERT | Director | Stock Award(Grant) | May 2, 2018 | 0 |
| HERENDEEN PAUL S | Chief Financial Officer | Stock Award(Grant) | Mar 6, 2018 | 216,492 |
| KARABELAS ARGERIS N | Director | Stock Award(Grant) | May 2, 2018 | 60,417 |
| KAVANAGH, SARAH BALDWIN | Director | Stock Award(Grant) | May 2, 2018 | 54,149 |
| PAULSON JOHN A. | Director | Stock Award(Grant) | May 2, 2018 | 37,361 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paulson & Company, Inc. | 5.98% | 20,839,035 | 440.95M | Dec 30, 2017 |
| ValueAct Holdings, L.P. | 5.16% | 18,010,027 | 381.09M | Dec 30, 2017 |
| Renaissance Technologies, LLC | 3.05% | 10,651,189 | 225.38M | Dec 30, 2017 |
| Vanguard Group, Inc. (The) | 2.30% | 8,007,068 | 169.43M | Dec 30, 2017 |
| Miller Value Partners, LLC | 1.94% | 6,748,159 | 142.79M | Dec 30, 2017 |
| Toronto Dominion Bank | 1.74% | 6,067,701 | 128.39M | Dec 30, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust for Advised Port-Miller Opportunity Trust | 1.32% | 4,600,000 | 97.34M | Dec 30, 2017 |
| Vanguard International Stock Index-Total Intl Stock Indx | 1.21% | 4,220,536 | 71.07M | Jul 30, 2017 |
| Oppenheimer Main Street Fund | 0.57% | 1,983,050 | 28.22M | Aug 30, 2017 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 0.47% | 1,629,657 | 27.13M | Jun 29, 2017 |
| Legg Mason Clearbridge Aggressive Growth Fd | 0.43% | 1,507,645 | 31.90M | Dec 30, 2017 |
| DFA International Core Equity Portfolio | 0.30% | 1,033,457 | 17.40M | Jul 30, 2017 |